286 related articles for article (PubMed ID: 26602073)
1. Effect of Randomized Lipid Lowering With Simvastatin and Ezetimibe on Cataract Development (from the Simvastatin and Ezetimibe in Aortic Stenosis Study).
Bang CN; Greve AM; La Cour M; Boman K; Gohlke-Bärwolf C; Ray S; Pedersen T; Rossebø A; Okin PM; Devereux RB; Wachtell K
Am J Cardiol; 2015 Dec; 116(12):1840-4. PubMed ID: 26602073
[TBL] [Abstract][Full Text] [Related]
2. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
[TBL] [Abstract][Full Text] [Related]
3. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study.
Rossebø AB; Pedersen TR; Allen C; Boman K; Chambers J; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi VA; Malbecq W; Nienaber C; Ray S; Skjaerpe T; Wachtell K; Willenheimer R
Am J Cardiol; 2007 Apr; 99(7):970-3. PubMed ID: 17398194
[TBL] [Abstract][Full Text] [Related]
4. Observed and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis trial.
Holme I; Boman K; Brudi P; Egstrup K; Gohlke-Baerwolf C; Kesäniemi YA; Malbecq W; Rossebø AB; Wachtell K; Willenheimer R; Pedersen TR
Am J Cardiol; 2010 Jun; 105(12):1802-8. PubMed ID: 20538134
[TBL] [Abstract][Full Text] [Related]
5. Effect Modifications of Lipid-Lowering Therapy on Progression of Aortic Stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study).
Greve AM; Bang CN; Boman K; Egstrup K; Forman JL; Kesäniemi YA; Ray S; Pedersen TR; Best P; Rajamannan NM; Wachtell K
Am J Cardiol; 2018 Mar; 121(6):739-745. PubMed ID: 29361285
[TBL] [Abstract][Full Text] [Related]
6. Incidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial.
Green A; Ramey DR; Emneus M; Iachina M; Stavem K; Bolin K; McNally R; Busch-Sørensen M; Willenheimer R; Egstrup K; Kesäniemi YA; Ray S; Basta N; Kent C; Pedersen TR
Am J Cardiol; 2014 Nov; 114(10):1518-22. PubMed ID: 25267716
[TBL] [Abstract][Full Text] [Related]
7. Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Greve AM; Bang CN; Boman K; Egstrup K; Kesäniemi YA; Ray S; Pedersen TR; Wachtell K
Am J Cardiol; 2019 Dec; 124(11):1736-1740. PubMed ID: 31586530
[TBL] [Abstract][Full Text] [Related]
8. Effect of simvastatin and ezetimibe on suPAR levels and outcomes.
Hodges GW; Bang CN; Forman JL; Olsen MH; Boman K; Ray S; Kesäniemi YA; Eugen-Olsen J; Greve AM; Jeppesen JL; Wachtell K
Atherosclerosis; 2018 May; 272():129-136. PubMed ID: 29602140
[TBL] [Abstract][Full Text] [Related]
9. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
11. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome.
Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM
J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516
[TBL] [Abstract][Full Text] [Related]
12. Effect of lipid lowering on new-onset atrial fibrillation in patients with asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
Bang CN; Greve AM; Boman K; Egstrup K; Gohlke-Baerwolf C; Køber L; Nienaber CA; Ray S; Rossebø AB; Wachtell K
Am Heart J; 2012 Apr; 163(4):690-6. PubMed ID: 22520536
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
14. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
15. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
16. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
17. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
18. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
[TBL] [Abstract][Full Text] [Related]
19. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Lancellotti P; Pierard LA; Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
[TBL] [Abstract][Full Text] [Related]
20. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]